A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors.

Clinical Trial Grant

Duke Scholars

Principal Investigator John Strickler Medicine, Medical Oncology

Awarded By

AbbVie Inc.

Start Date

July 1, 2016

End Date

June 30, 2020

Awarded By

AbbVie Inc.

Start Date

July 1, 2016

End Date

June 30, 2020